Saxenda vs Wegovy: Which GLP-1 Is Better?

Saxenda and Wegovy are both FDA-approved GLP-1 receptor agonists for chronic weight management, but they differ in significant ways — from weight loss effectiveness to dosing frequency to cost. If you're comparing Saxenda vs Wegovy to determine which GLP-1 medication might be right for you, this comprehensive guide breaks down everything you need to know, including clinical trial results, side effects, pricing, and practical considerations.

Quick Comparison: Saxenda vs Wegovy at a Glance

How Saxenda Works

Saxenda contains liraglutide, a GLP-1 receptor agonist with a half-life of approximately 13 hours. Because it's cleared from the body relatively quickly, it requires daily injections to maintain therapeutic levels.

Saxenda Dosing Schedule

The titration schedule for Saxenda spans 5 weeks:

• Week 1: 0.6 mg daily
• Week 2: 1.2 mg daily
• Week 3: 1.8 mg daily
• Week 4: 2.4 mg daily
• Week 5 and beyond: 3.0 mg daily (maintenance dose)

Saxenda Clinical Results

In the SCALE clinical trial program:

• Participants lost an average of 5–8% of body weight over 56 weeks
• Approximately 63% of participants lost at least 5% of their body weight
• Approximately 33% lost at least 10% of their body weight
• Improvements were observed in blood pressure, cholesterol, and blood sugar markers

How Wegovy Works

Wegovy contains semaglutide, a newer GLP-1 receptor agonist with a half-life of approximately 7 days. This extended half-life allows for once-weekly dosing, which many patients find more convenient.

Wegovy Dosing Schedule

The titration schedule for Wegovy spans approximately 16–20 weeks:

• Weeks 1–4: 0.25 mg weekly
• Weeks 5–8: 0.5 mg weekly
• Weeks 9–12: 1.0 mg weekly
• Weeks 13–16: 1.7 mg weekly
• Week 17 and beyond: 2.4 mg weekly (maintenance dose)

Wegovy Clinical Results

In the STEP clinical trial program:

• Participants lost an average of 15–17% of body weight over 68 weeks
• Approximately 86% of participants lost at least 5% of their body weight
• Approximately 69% lost at least 10% of their body weight
• Approximately 50% lost at least 15% of their body weight
• The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events

Head-to-Head: Weight Loss Effectiveness

The weight loss difference between Saxenda and Wegovy is substantial and consistently favored Wegovy across studies:

• Wegovy produces roughly 2–3 times more weight loss than Saxenda on average
• In the STEP 8 trial (which directly compared semaglutide 2.4 mg to liraglutide 3.0 mg), semaglutide produced 15.8% body weight loss vs. 6.4% for liraglutide over 68 weeks
• More Wegovy patients achieved clinically meaningful weight loss thresholds (≥10%, ≥15%, ≥20%)

The bottom line: If weight loss effectiveness is your primary consideration, clinical data clearly favors Wegovy over Saxenda.

Side Effects Comparison

Both medications share a similar side effect profile, as expected for GLP-1 receptor agonists. However, there are some differences worth noting.

Common Side Effects

Key Differences in Side Effects

• Saxenda's nausea tends to be milder but more constant due to daily dosing
• Wegovy's side effects may be more intense but intermittent, often peaking 1–2 days after the weekly injection
• Gallbladder events appear slightly more common with Wegovy, likely due to more rapid weight loss
• Both carry the same boxed warning regarding thyroid C-cell tumors

Discontinuation Rates Due to Side Effects

• Saxenda: Approximately 6–10% of patients discontinued due to adverse events in clinical trials
• Wegovy: Approximately 7% of patients discontinued due to adverse events

Cost Comparison

List Prices (Without Insurance)

• Saxenda: Approximately $1,200–$1,500 per month
• Wegovy: Approximately $1,300–$1,700 per month

Insurance Coverage

Both medications are FDA-approved for weight management, which can help with insurance coverage. However:

• Saxenda has been on the market longer (since 2014) and may have broader formulary coverage
• Wegovy is increasingly covered but may face more prior authorization requirements
• Some insurers require patients to try Saxenda (or other interventions) before approving Wegovy (step therapy)
• Coverage for weight management medications varies dramatically by insurer and plan

Savings Programs

Both medications offer manufacturer savings programs through Novo Nordisk:

• Eligible commercially insured patients may access significant copay assistance
• Patient assistance programs exist for uninsured patients
• Check with your pharmacy and insurer for the most current options

Convenience and Lifestyle Factors

Injection Frequency

This is often the deciding factor for many patients:

• Saxenda: Daily injections (365 injections per year)
• Wegovy: Weekly injections (52 injections per year)

Many patients strongly prefer the convenience of weekly dosing with Wegovy. Research suggests that less frequent dosing improves medication adherence.

Storage and Travel

• Saxenda: The multi-dose pen is used for multiple days; once in use, it can be stored at room temperature for up to 30 days
• Wegovy: Each pen is single-use; unopened pens must be refrigerated but can be kept at room temperature for up to 28 days

Injection Experience

• Saxenda: The pen allows dose adjustment, which can be useful during titration
• Wegovy: Pre-filled single-dose pens — no dose adjustment needed; simpler to use

Cardiovascular Benefits

This is an important area of differentiation:

• Wegovy: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in overweight/obese adults without diabetes. This is a significant clinical finding.
• Saxenda: The LEADER trial showed cardiovascular benefits for liraglutide in diabetes patients, but no equivalent large-scale cardiovascular outcome trial has been conducted specifically for Saxenda in a weight management population.

For patients with cardiovascular risk factors, the proven CV benefits of Wegovy may be a decisive advantage.

Who Might Choose Saxenda Over Wegovy?

Despite Wegovy's advantages in efficacy, there are scenarios where Saxenda might be the better choice:

• Insurance requires it: Some plans require trying Saxenda before approving Wegovy
• Wegovy is unavailable: Supply shortages have affected Wegovy availability
• Dose flexibility needed: Saxenda's adjustable pen allows more granular dose control
• Lower cost option found: In some cases, Saxenda may be more affordable based on specific insurance plans or discount programs
• Preference for gradual effect: Some patients prefer the more gradual onset of daily dosing
• Adolescent use: Both are approved for ages 12+, but Saxenda has a longer track record in this population

Who Might Choose Wegovy Over Saxenda?

For most patients, Wegovy offers clear advantages:

• Greater weight loss: Approximately 2–3x more effective for weight reduction
• Weekly dosing: Far more convenient than daily injections
• Cardiovascular benefits: Proven reduction in major cardiovascular events
• Simpler administration: Pre-filled pens with no dose adjustment needed
• Potentially better adherence: Weekly dosing is easier to maintain long-term

Frequently Asked Questions

Can I switch from Saxenda to Wegovy?

Yes, switching from Saxenda to Wegovy is possible and relatively common. Your healthcare provider will typically stop Saxenda and start Wegovy at the lowest dose (0.25 mg weekly), following the standard titration schedule. Some providers may accelerate the titration slightly since your body is already adjusted to a GLP-1 medication, but this varies by individual.

Is Saxenda safer than Wegovy?

Both medications have well-established safety profiles and carry similar risks. Saxenda has been on the market longer (since 2014 vs. 2021 for Wegovy), providing more long-term real-world safety data. However, semaglutide (Wegovy's active ingredient) has been extensively studied across multiple large-scale clinical trials. Neither medication is inherently "safer" — the choice should be based on your individual health profile and discussion with your provider.

Why would a doctor prescribe Saxenda instead of Wegovy?

Providers might prescribe Saxenda for several reasons: insurance requires trying Saxenda first (step therapy), Wegovy supply is limited in your area, you've had issues with weekly injections in the past, or cost considerations favor Saxenda for your specific situation. Some providers also prefer starting with Saxenda for patients who are anxious about starting GLP-1 treatment, since the daily dosing allows for more gradual adjustment.

Can I take Saxenda and Wegovy together?

No. You should never take two GLP-1 receptor agonists simultaneously. This would increase the risk of serious side effects, including severe gastrointestinal symptoms, pancreatitis, and dangerous blood sugar drops. If you're considering a change, your provider will guide a safe transition from one medication to the other.

Which has fewer side effects, Saxenda or Wegovy?

Side effect profiles are similar between both medications. Saxenda may cause less intense nausea at any given time due to its shorter-acting nature, but the daily dosing means side effects are more constant. Wegovy's side effects tend to peak after each weekly injection and improve as the week progresses. Overall discontinuation rates due to side effects are comparable between the two medications.

Taking the Next Step

Both Saxenda and Wegovy are effective FDA-approved options for chronic weight management. While clinical data clearly favors Wegovy for weight loss effectiveness and cardiovascular benefits, the right choice depends on your individual health profile, insurance coverage, availability, and personal preferences.

The best way to determine which medication is right for you is to consult with a qualified healthcare provider who can evaluate your specific situation.

Ready to explore your options? Take our free eligibility quiz →

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.